Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain

Inclusion Criteria

• •≥ 18 years of age or older, with moderate to severe chronic malignant and/or neuropathic pain of at least 3 months duration and either:
• •1. have an initial pain intensity score of greater than 4 on a 10-point scale using BPI Question 5, if sub-optimally responding to their current analgesic regimen, or
• •2. have intolerable side effects to one or more components of their current opioid-containing analgesic regimen.
• •Currently receive a stable (at least 2 weeks duration) analgesic regimen
• •If female, must be practicing abstinence or using a medically acceptable form of contraception (e.g., intrauterine device, hormonal birth control, or double barrier method).
• •Understand written and spoken English
• •Have been informed of the nature of the study and provided written informed consent
• •Have a life expectancy of at least 12 months
• •Have a diagnosis of:
• •* post-herpetic neuralgia (PHN)
• •* diabetic neuropathy (DN)
• •* complex regional pain syndrome (CRPS)
• •* HIV neuropathy
• •* idiopathic sensory neuropathy
• •* traumatic peripheral neuropathy
• •* central neuropathic pain condition (spinal cord injury, post-stroke pain), OR
• •* other peripheral neuropathy (upon mutual agreement of the sponsor and investigator).